Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06796348 | Radiofrequency Ablation Versus Hemithyroidectomy for Small Thyroid Cancers | recruiting | N/A | 88 | University of AarhusOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06806852 | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | active not recruiting | Phase 1 | 91 | Boehringer IngelheimINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07630168 | Effects of Infusion Timing on Treatment Response in Solid Tumors(TIMED) | recruiting | Phase 2 | 238 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07783321 | A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07809776 | Tai Chi for Cancer-Related Fatigue During Radiotherapy in Patients With Head and Neck Cancer | recruiting | N/A | 116 | West China HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819617 | Submental Island Flap vs Radial Forearm Free Flap in Tongue Reconstruction(SIPF-RFFF) | completed | — | 28 | Al-Azhar UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819656 | Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma | recruiting | — | 1,782 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07821242 | Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma(NCRHNC) | not yet recruiting | Phase 2 | 46 | Ke HuOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00467506 | Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma(RIT in MTC) | completed | Phase 2 | — | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00542373 | Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer | active not recruiting | N/A | 338 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01709292 | Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | active not recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02734537 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | recruiting | Phase 2 | 189 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03493425 | Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | active not recruiting | Phase 2 | 82 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03888651 | Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers | active not recruiting | — | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04191460 | Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer(GuidedbyLight) | completed | Phase 2 | 31 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04255849 | Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV | active not recruiting | Phase 3 | 700 | Weill Medical College of Cornell UniversityOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT04285476 | Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type(PREDICYTHY) | active not recruiting | N/A | 71 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05752149 | Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial(STELLAR) | recruiting | Phase 2 | 27 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06064097 | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07513389 | Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) | recruiting | Phase 2 | 36 | Medical University of South CarolinaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818486 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01199978 | Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05187091 | The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas(SWOAR) | recruiting | Phase 3 | 136 | All India Institute of Medical SciencesOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05648461 | Phase II Study Exploring Five Fractions of Post-operative Radiation Therapy in Head and Neck Cancer(Accelerate) | withdrawn | N/A | 0 | All India Institute of Medical SciencesOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05710679 | Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer(NeckTAR) | recruiting | N/A | 63 | Centre Jean PerrinOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06055868 | People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity | active not recruiting | — | 133 | University of California, San FranciscoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06307418 | Internet-based Support for Informal Caregivers of Patients With Head and Neck Cancer - Carer eSupport | active not recruiting | N/A | 110 | Uppsala UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06487403 | HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers(HN-Bio 02) | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06557889 | Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas(REDUCE) | active not recruiting | Phase 2 | 86 | Institut Claudius RegaudOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06722508 | Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients | recruiting | N/A | 20 | University of California, DavisOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07178847 | cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas(NeckTAR-IN) | recruiting | N/A | 59 | Centre Jean PerrinOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | suspended | Phase 1 | 90 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07218315 | Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma | recruiting | N/A | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814872 | A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment(FATHOM) | not yet recruiting | — | 30,000 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815522 | Abiraterone With Dalpiciclib in Salivary Gland Carcinoma | recruiting | Phase 2 | 36 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02135042 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | active not recruiting | Phase 2 / Phase 3 | 924 | NRG OncologyOTHER | 8 | Sep 10, 2026 | clinicaltrials |
| NCT03647358 | Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma | recruiting | Phase 1 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04868162 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | completed | Phase 2 | 70 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05546827 | Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials